Skip to content

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

Acute Coronary Syndrome

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).

null

Conditions de participation

  • Sexe:

    ALL
  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:

* Participants must have an index event that meets all 3 of the following criteria within 7 days prior to randomization: a) clinical syndrome consistent with spontaneous cardiac ischemia, b) diagnosis of acute coronary syndrome (ACS) (that is, ST-elevation myocardial infarction \[STEMI\], non-STEMI, or unstable angina \[UA\]), c) cardiac biomarker elevation (example, troponin I, troponin T, creatine kinase-MB \[CK-MB\]) above the upper limit of normal as determined by the local laboratory
* Participants must have at least 2 of the following risk factors:a) age 65 or older, b) diabetes mellitus, c) history of a prior myocardial infarction (MI) (other than index ACS event), d) multivessel coronary artery disease (CAD), e) history of coronary artery bypass graft (CABG) surgery prior to index ACS event, f) history of peripheral artery disease (PAD) or cerebrovascular disease (example, carotid atherosclerosis, intracranial artery stenosis, g) conservative management (that is, no percutaneous intervention \[PCI\] or CABG after index ACS event), h) Any one or more of the following high-risk angiographic features i) total stent length of greater than (\>) 30 millimeters (mm), ii) thrombotic target lesion, iii) bifurcation lesion treated with more than one stent, iv) calcified target lesion treated with atherectomy, v) treatment of obstructive left main or proximal left anterior descending artery for index ACS (or clinical diagnosis of an anterior STEMI)
* All female participants of childbearing potential must have a negative highly sensitive serum beta-human chorionic gonadotropin (hCG) or urine test at screening
* A female participant must not be pregnant, breastfeeding, or planning to become pregnant until 4 days (5 half-lives) after the last dose of study intervention

Exclusion Criteria:

* MI secondary to ischemia due to either increased oxygen demand or decreased supply (Type 2 MI) or periprocedural MI as the index ACS event
* Planned CABG or staged PCI after randomization
* Any condition that requires chronic anticoagulation at the discretion of the investigator and/or local guidelines
* Conditions with a significant increased risk of bleeding (example, clinically significant bleeding within previous 3 months, known bleeding diathesis, et cetera)

Lieu de l'étude

Foothills Hospital
Foothills Hospital
Calgary, Alberta
Canada

Contactez l'équipe d'étude

Saint Boniface General Hospital
Saint Boniface General Hospital
Winnipeg, Manitoba
Canada

Contactez l'équipe d'étude

London Health Sciences Centre
London Health Sciences Centre
London, Ontario
Canada

Contactez l'équipe d'étude

Kawartha Cardiology Clinical Trials
Kawartha Cardiology Clinical Trials
Peterborough, Ontario
Canada

Contactez l'équipe d'étude

Clinique de Cardiologie de Levis
Clinique de Cardiologie de Levis
Levis, Quebec
Canada

Contactez l'équipe d'étude

CSSS du Sud de Lanaudiere - Hopital Pierre-Le Gardeur d/b/a CISSS de Lanaudiere
CSSS du Sud de Lanaudiere - Hopital Pierre-Le Gardeur d/b/a CISSS de Lanaudiere
Terrebonne, Quebec
Canada

Contactez l'équipe d'étude

Vancouver General Hospital
Vancouver General Hospital
Vancouver, British Columbia
Canada

Contactez l'équipe d'étude

Hamilton Health Sciences Corporation
Hamilton Health Sciences Corporation
Hamilton, Ontario
Canada

Contactez l'équipe d'étude

University of Ottawa Heart Institute
University of Ottawa Heart Institute
Ottawa, Ontario
Canada

Contactez l'équipe d'étude

Office of Dr. Anthony Glanz
Office of Dr. Anthony Glanz
Windsor, Ontario
Canada

Contactez l'équipe d'étude

CardioVasc HR
CardioVasc HR
St Jean sur Richelieu, Quebec
Canada

Contactez l'équipe d'étude

University of Alberta
University of Alberta
Edmonton, Alberta
Canada

Contactez l'équipe d'étude

Dalhousie University
Dalhousie University
Halifax, Nova Scotia
Canada

Contactez l'équipe d'étude

Southlake Regional Health Centre
Southlake Regional Health Centre
Newmarket, Ontario
Canada

Contactez l'équipe d'étude

Niagara Health System
Niagara Health System
St Catharines, Ontario
Canada

Contactez l'équipe d'étude

Centre de Recherche du CHUM
Centre de Recherche du CHUM
Montreal, Quebec
Canada

Contactez l'équipe d'étude

CIUSSS de la Mauricie-et-du-Centre-du-Quebec
CIUSSS de la Mauricie-et-du-Centre-du-Quebec
Trois-Rivières, Quebec
Canada

Contactez l'équipe d'étude

Surrey Memorial Hospital
Surrey Memorial Hospital
Surrey, British Columbia
Canada

Contactez l'équipe d'étude

Dr. Saul Vizel Cardiac Research Office
Dr. Saul Vizel Cardiac Research Office
Cambridge, Ontario
Canada

Contactez l'équipe d'étude

Halton Healthcare Services Corporation
Halton Healthcare Services Corporation
Oakville, Ontario
Canada

Contactez l'équipe d'étude

Toronto Sunnybrook Hospital
Toronto Sunnybrook Hospital
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Montreal General Hospital
Montreal General Hospital
Montreal, Quebec
Canada

Contactez l'équipe d'étude

Royal University Hospital
Royal University Hospital
Saskatoon, Saskatchewan
Canada

Contactez l'équipe d'étude

Étude parrainée par
Janssen Research & Development, LLC
Participants recherchés
Plus d'informations
ID de l'étude: NCT05754957